Respiratory Panel

Acute Respiratory Infections (ARIs) are responsible for 4.25 million deaths annually and are the third largest cause of mortality in the world. Rapid assays at the point of care have been helpful in particular situations but still offer very limited data because they only test for one pathogen. The Infinite Genomics InGenDx Respiratory Panel is a state-of-the-art molecular diagnostic solution designed to revolutionize the diagnosis and treatment of acute respiratory infections (ARIs). ARIs are a significant cause of mortality worldwide, and rapid and accurate diagnostics are crucial for effective management. Our advanced molecular methodology enables the simultaneous detection of multiple pathogens, providing clinicians with comprehensive information for timely and targeted treatment decisions.

Clinical Advantages:

  • Timely Diagnosis and Treatment:

    The Respiratory Pathogen Panel offers quick results, typically within 24 to 48 hours after the specimen arrives at the lab. This prevents delays in diagnosis and enables early initiation of appropriate treatment, optimizing patient outcomes.

  • Simultaneous Detection of Polymicrobial Infections:

    The panel detects multiple pathogens associated with respiratory infections simultaneously. This comprehensive approach allows for accurate identification of coexisting infections, guiding targeted treatment strategies.

  • Identification of Antibiotic Resistance Genes:

    The Respiratory Pathogen Panel identifies multiple antibiotic resistance genes across various antibiotic categories, including Carbapenem, and Vancomycin resistance. This information empowers clinicians to select effective antimicrobial therapies and avoid antibiotics to which the identified pathogens may be resistant.

  • Reduction of Unnecessary Drug Exposure and Adverse Events:

    By providing precise information on pathogen identification and antibiotic resistance profiles, the Respiratory Pathogen Panel minimizes unnecessary drug exposure, reducing the risk of adverse events and optimizing treatment outcomes.

  • Control of Infection Progression and Spread:

    Early and accurate detection of respiratory pathogens aids in controlling the progression and spread of infection. Timely intervention minimizes complications and the risk of secondary infections, improving patient outcomes.

  • Up-to-Date Regional Sensitivity and Susceptibility Patterns:

    The panel incorporates regional sensitivity and susceptibility patterns, providing clinicians with the most current information on local pathogen trends. This knowledge enhances the selection of narrow-spectrum antibiotics, improving treatment efficacy and minimizing the risk of resistance development.

  • Facilitates Cost-Effective Treatment Decisions:

    By considering regional sensitivity and resistance patterns, the Respiratory Pathogen Panel supports clinicians in making cost-effective treatment decisions. It assists in selecting the most appropriate and affordable treatment options while optimizing patient outcomes.

  • Accessible Results:

    The panel delivers easily accessible results through various channels, including mobile devices, web portals, and seamless integration with electronic medical records (EMR). This accessibility ensures convenient and efficient access to critical diagnostic information for timely treatment decisions.

The Infinite Genomics InGenDx Respiratory Panel revolutionizes the management of acute respiratory infections, providing clinicians with rapid and accurate diagnostic information for tailored treatment plans. By preventing delays, improving selection of antibiotics, and reducing unnecessary drug exposure, the panel enhances patient care and contributes to better treatment outcomes.